Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 May 13;5(5):CD007572.
doi: 10.1002/14651858.CD007572.pub4.

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

Johannes Hasskamp  1 , Christian Meinhardt  2 , Antje Timmer  1
Affiliations
Meta-Analysis

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

Johannes Hasskamp et al. Cochrane Database Syst Rev. .

Abstract

Background: Crohn's disease (CD) is a chronic inflammatory bowel disease leading to symptoms such as abdominal pain, diarrhea, weight loss, fatigue, and complications such as strictures and fistulas. Ustekinumab (CNTO 1275) and briakinumab (ABT-874) are monoclonal antibodies that target the standard p40 subunit of the cytokines interleukin-12 and interleukin-23 (IL-12/23p40), which are involved in the pathogenesis of CD. Briakinumab has been withdrawn for the treatment of CD, making ustekinumab the only available antibody against the p40 subunit of interleukin-12 and interleukin-23 approved for this purpose.

Objectives: To assess the benefits and harms of anti-IL-12/23p40 antibodies for induction of remission in CD, as compared to no treatment, placebo, other drug treatment, or varying dosing schedules.

Search methods: We searched the following databases: Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, and MEDLINE (from inception to 2 February 2024) and Embase (from inception until 12 August 2022). We also searched ClinicalTrials.gov, WHO ICTRP, references, and conference abstracts to identify additional studies.

Selection criteria: We included randomized controlled trials (RCTs) of at least four weeks' duration in which monoclonal antibodies against IL-12/23p40 were compared to placebo, no treatment, or another active comparator in people with active CD. We also included trials examining different doses of antibodies against IL-12/23p40.

Data collection and analysis: Two review authors independently screened studies for inclusion and extracted data. We assessed the methodological quality of the included studies using Cochrane's RoB 2 tool. The primary outcome was failure to induce clinical remission by week 8, or 6 to 12 as available. Secondary outcomes included failure to induce clinical improvement (clinical response), induction of endoscopic remission, quality of life, and adverse events, serious adverse events, and withdrawals due to adverse events. We calculated the risk ratio (RR) or risk difference (RD) and 95% confidence intervals (95% CI) for each outcome unless substantial heterogeneity was detected. We analyzed data on an intention-to-treat basis. We assessed the certainty of the evidence using the GRADE approach.

Main results: Eight RCTs involving a total of 3224 participants with CD met the inclusion criteria. All studies were double-blinded. We assessed the risk of bias for most outcomes as either low risk of bias or some concerns. Based on a pooled analysis of three trials, ustekinumab decreased the number of participants failing to achieve clinical remission at eight weeks when compared to placebo. Seventy-four per cent (693/938) of participants in the ustekinumab group and 87% (421/483) of those in the placebo group did not enter clinical remission (RR 0.85, 95% CI 0.81 to 0.89; 3 studies; 1421 participants; high-certainty evidence). Treatment with ustekinumab likely did not lead to more serious adverse events when compared to placebo, with 5% (48/966) and 6% (30/505) of participants affected in the ustekinumab and placebo groups, respectively (RD -0.01, 95% CI -0.03 to 0.01; 3 studies; 1471 participants; moderate-certainty evidence). A single small study in children compared two different induction doses of ustekinumab. The evidence for this outcome is very uncertain due to wide CIs. Eighty-one per cent (17/21) of participants receiving the higher induction dose (9 mg/kg or 390 mg) did not enter clinical remission at eight weeks, compared to 78% (18/23) of participants receiving the lower induction dose of 3 mg/kg or 130 mg (RR 1.03, 95% CI 0.77 to 1.39; 1 study; 44 participants; very low-certainty evidence). Separate safety data for the eight-week time point were not available for this comparison. Based on one trial comparing ustekinumab to adalimumab, the evidence is very uncertain about which is the more beneficial drug. Fifty per cent (95/191) of participants receiving ustekinumab did not enter remission compared to 52% (101/195) of participants receiving adalimumab (RR 0.96, 95% CI 0.79 to 1.17; 1 study; 386 participants; very low-certainty evidence). Separate results on adverse events at eight weeks were not reported for this comparison.

Authors' conclusions: Ustekinumab reduces the risk of people with CD failing to enter clinical remission at eight weeks. It probably does not lead to more serious adverse events when compared to placebo. There were inadequate data to conclude the more effective induction dose of ustekinumab in children. No studies evaluated adverse events at eight weeks for this comparison. There may be little to no difference between ustekinumab and other biologics, such as adalimumab or guselkumab, in inducing clinical remission at week 8, but the evidence is very uncertain, and separate data on adverse events at eight weeks were not available.

Trial registration: ClinicalTrials.gov NCT02877134 NCT02968108 NCT03466411 NCT03464136 NCT03107793 NCT01369355 NCT04655807 NCT03782376 NCT04496063 NCT04524611 NCT04629196 NCT05928039.

PubMed Disclaimer

Conflict of interest statement

Johannes Hasskamp, Christian Meinhardt, and Antje Timmer declare that they have no conflict of interest.

Update of

References

References to studies included in this review

Allez 2023 {published data only}
    1. Allez M, Sands BE, Feagan BG, D'Haens G, De Hertogh G, Randall CW, et al. A phase 2b, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study evaluating the safety and efficacy of tesnatilimab in patients with moderately to severely active Crohn's disease. Journal of Crohn's & Colitis 2023;17(8):1235-51. [DOI: 10.1093/ecco-jcc/jjad047] - DOI - PubMed
Feagan 2016 UNITI‐1 {published data only}
    1. Adedokun OJ, Xu Z, Gasink C, Szapary P, Johanns J, Gao LL, et al. Pharmacokinetics and exposure-response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI-1, UNITI-2, and IM-UNITI studies. Gastroenterology 2016;150(4 Suppl 1):S408.
    1. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine 2016;375(20):1946-60. - PubMed
    1. Li K, Hayden K, Wadman E, Bhagat S, Emrich S, Jacobstein D, et al. Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein analysis: Results from UNITI-1 induction, UNITI-2 induction, and IMUNITI maintenance studies. Gastroenterology 2016;150(4 Suppl 1):S377.
    1. Sandborn W, Gasink C, Blank M, Lang Y, Johanns J, Gao LL, et al. A multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti-TFNalpha: UNITI-1. Inflammatory Bowel Diseases 2016;22(Suppl 1):S1.
    1. Sandborn W, Gasink C, Jacobstein D, Gao LL, Johanns J, Targan S, et al. Assessment of serum C-reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate-severely active Crohns disease: Results from the IM UNITI maintenance study. Gastroenterology 2016;150(4 Suppl 1):S982.
Feagan 2016 UNITI‐2 {published data only}
    1. Feagan B, Gasink C, Lang Y, Friedman JR, Johanns J, Gao LL. A multicenter, double-blind, placebo-controlled pH3 study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately-severely active Crohn's disease who are not naive or not refractory to anti-TNFa: UNITI-2. United European Gastroenterology Journal 2015;3(6):563-4.
Rosh 2021 {published data only}
    1. Adedokun OJ, Hyams JS, Turner D, Griffiths AM, Terry NA, Padgett L, et al. 615: Pharmacokinetics of ustekinumab in children and adolescents with moderately to severely active Crohn's disease: Results from UniStar, a phase 1 study. Gastroenterology 2020;158(6):S131-32.
    1. Rosh JR, Turner D, Griffiths AM, Cohen SA, Jacobstein D, Adedokun OJ, et al. Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Pharmacokinetics, safety, and efficacy results from UniStar, a Phase 1 study. Journal of Crohn's & Colitis 2021;15(11):1931-42. [DOI: 10.1093/ecco-jcc/jjab089] - DOI - PMC - PubMed
    1. Rosh JR, Turner D, Griffiths AM, Jacobstein D, Adedokun OJ, Padgett L, et al. 1164: Efficacy, safety, tolerability of ustekinumab in pediatric patients with moderately to severely active Crohn's disease: Results from UniStar, a phase 1 study. Gastroenterology 2020;158(5):S235-36.
Sandborn 2008 {published data only (unpublished sought but not used)}
    1. Sandborn W, Feagan B, Fedorak R, Scherl E, Fleisher M, Katz S, et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL- 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases 2008;14(Supp 1):S10.
    1. Sandborn WJ, Feagan BG, Fedorak R, Scherl E, Fleisher M, Katz S, et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL-12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology 2007;132(4 Suppl 1):A51.
    1. Sandborn WJ, Feagan BG, Fedorak R, Scherl E, Fleisher M, Katz S, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135(4):1130-41. - PubMed
    1. Toedter GP, Blank M, Lang Y, Chen D, Sandborn WJ, Villiers WJ. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology 2009;104(11):2768-73. - PubMed
Sandborn 2012 {published data only}
    1. Ding T, Telesco S, Monast CS, Brodmerkel C, Yatsunenko T, Das A, et al. The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study. Gastroenterology 2015;148:S-713.
    1. Ding T, Telesco S, Monast CS, Brodmerkel C, Yatsunenko T, Das A, et al. The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study. United European Gastroenterology Journal 2015;3(5 Suppl 1):A133-4.
    1. Feagan B, Gasink C, Gao L, Blank M, Johanns J, Guzzo C, et al. A multicenter, randomized, double-blind, placebo-controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL-12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology 2011;106:S-463.
    1. Feagan B, Gasink C, Gao LL, Blank M, Johanns J, Guzzo C, et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's & Colitis 2012;6(Supp 1):S129-30.
    1. Gasink C, Chan D, Gao LL, Schenkel B, Han C. Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology 2013;144(5 Suppl 1):S231.
Sandborn 2022 {published data only}
    1. Afzali A, Sandborn WJ, Hisamatsu T, Weisel K, Gonzalez S, Frustaci ME, et al. S748: Early PRO-2 symptom remission following guselkumab induction treatment: Results through week 12 of the phase 2 GALAXI 1 study. American Journal of Gastroenterology 2021;116:S344-5.
    1. Danese S, Panaccione R, Rubin DT, Sands BE, Reinisch W, D'Haens GR, et al. OP24: Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's Disease: Week 48 analyses from the phase 2 GALAXI 1 study. Journal of Crohn's & Colitis 2022;16(Supplement_1):i026-7.
    1. Leong RW, D'Haens GR, Rubin DT, Panes J, Gonzalez S, Chan D, et al. 18: Effect of guselkumab induction therapy on endoscopic outcome measures in patients with moderately to severely active Crohn's disease: Week 12 results from the Phase 2 GALAXI 1 study. Journal of Gastroenterology and Hepatology 2021;36(S3):169-70.
    1. Panaccione R, Rubin DT, Sands BE, Reinisch W, D'Haens GR, Panés J, et al. 888: Efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's disease: Week 48 analyses from the phases 2 GALAXI 1 study. Gastroenterology 2022;162(7):S-216-7.
    1. Panés J, Panaccione R, D'Haens GR, Han C, Gonzalez S, Weisel K, et al. P0403: Patient-reported outcomes of response and remission following guselkumab induction treatment measured by the inflammatory bowel disease questionnaire: Results through week 12 of the phase 2 GALAXI study. United European Gastroenterology Journal 2021;9(S8):497-8.
Sands 2022 {published data only}
    1. Allez M, Lewis JD, Hanauer SB, Danese S, Irving PM, Gasink C, et al. Su1513: Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study. Gastroenterology 2022;162(7):S-608-9.
    1. Danese S, Sands BE, Irving PM, Hoops T, Izanec JL, Ma T, et al. B15 | The Pharmacokinetics and immunogenicity of ustekinumab and adalimumab in patients with moderate-to-severe Crohn's disease: Results from the SEAVUE study. United Euopean Gastroenterology Journal 2021;9(10):1215-7.
    1. Ding Z, Muser E, Hoops T, Izanec JL, Ma T, Gao LL, et al. S723: Improvements in work productivity loss and associated cost reductions with ustekinumab and adalimumab in biologic-naïve patients with moderately-to-severely active Crohn’s disease: Results from the SEAVUE study. American Journal of Gastroenterology 2021;116:S330.
    1. Lewis JD, Allez M, Irving PM, Hoops T, Izanec JL, Ma T, et al. S851: Health-related quality of life with ustekinumab vs adalimumab for induction and maintenance therapy in biologic-naive patients with moderate-to-severe Crohn’s disease: PROMIS-29 in the SEAVUE study. American Journal of Gastroenterology 2021;116:S395-6.
    1. Loftus EV, Danese S, Panaccione R, Hoops T, Izanec JL, Ma T, et al. S770: Health-related quality of life with ustekinumab vs adalimumab for induction and maintenance therapy in biologic-naive patients with moderate-to-severe Crohn’s disease: IBDQ in the SEAVUE study. American Journal of Gastroenterology 2021;116:S394-5.

References to studies excluded from this review

Danese 2022 {published data only}
    1. D'Haens GR, Adedokun OJ, Danese S, Vermeire S, Panés J, Dignass A, et al. Su446: Pharmacokinetics, immunogenicity, and exposure-response reationship of ustekinumab in patients with Crohn's disease: Results from the week 16 interim analysis of the STARDUST study. Gastroenterology 2021;160(6):S-694.
    1. Danese S, Vermeire S, D'Haens GR, Panes J, Dignass A, Magro F, et al. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterology & Hepatology 2022;7(4):294-306. [DOI: 10.1016/ S2468-1253(21)00474-X] - PubMed
    1. Danese S, Vermeire S, D'Haens GR, Panés J, Dignass A, Magro F, et al. Sa073: Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results from a week 16 interim analysis of the STARDUST trial. Gastroenterology 2021;160(6):S-409. - PMC - PubMed
    1. Danese S, Vermeire S, D'Haens GR, Panés J, Dignass A, Magro F, et al. Tu1864: Endoscopic response to induction with ustekinumab in Crohn's disease: STARDUST interim analyses. Gastroenterology 2020;158(6):S-1193-94.
    1. Kucharzik T, Wilkens R, D'Agostino MA, Maconi G, Le Bars M, Lahaye M, et al. Early ultrasound response and progressive transmural remission after treatment with ustekinumab in Crohn's disease. Clinical Gastroenterology and Hepatology 2023;21(1):153-63. [DOI: 10.1016/j.cgh.2022.05.055] - DOI - PubMed
Fasanmade 2008 {unpublished data only}
    1. Fasanmade AA, Adedokun OJ, Johanns JR, Zhou H, Davis HM, Blank M. Pharmacokinetics and exposure-response relationship of ustekinumab, a human monoclonal antibody to interleukin 12/23 in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;134(4 Suppl 1):A-490.
Feagan 2016 IM‐UNITI {published data only}
    1. Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, et al. OP006: Exposure-response to sc ustekinumab in moderate-severe Crohn's disease: Results from the IM-UNITI maintenance study. United European Gastroenterology Journal 2017;5(5S):A3.
    1. Feagan BG, Gasink C, Pollack P, Jacobstein D, Gao LL, Johanns J, et al. P549: Effect of maintenance ustekinumab on corticosteroid-free clinical outcomes in patients with Crohn's disease. Journal of Crohn's & Colitis 2017;11(Suppl_1):S359-60.
    1. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. New England Journal of Medicine 2016;375(20):1946-60. [DOI: 10.1056/NEJMoa1602773] - DOI - PubMed
    1. Feagan BG, Sattin BD, Tornatore V, Gasink C, Gao LL, Sloan S, et al. Su1793: Outcomes of maintenance ustekinumab therapy for Crohn's disease based on inflammatory burden: A post-hoc analysis of the UNITI trials. Gastroenterology 2018;154(6):S-586.
    1. Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein C, Zou B, et al. IM-UNITI: Three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's disease. Journal of Crohn's & Colitis 2020;14(1):23-32. [DOI: 10.1093/ecco-jcc/jjz110] - DOI - PubMed
Mannon 2004 {published data only}
    1. Mannon P, Fuss I, Mayer L, Elson CO, Sandborn WJ, Dolin B, et al. Anti-interleukin-12 treats active Crohn's disease. Gastroenterology 2004;126(4 Suppl 2):A22-3.
    1. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Crohn's disease. New England Journal of Medicine 2004;351(20):2069-79. - PubMed
Murate 2020 {published data only}000028506
    1. Murate K, Maeda K, Nakamura M, Sugiyama D, Wada H, Yamamura T, et al. Endoscopic activity and serum TNF-α level at baseline are associated with clinical response to ustekinumab in Crohn’s disease patients. Inflammatory Bowel Diseases 2020;26(11):1669-81. [DOI: 10.1093/ibd/izaa086] - DOI - PubMed
NCT04655807 {published data only}
    1. NCT04655807. A study of JNJ-64304500 as add-on therapy in participants with active Crohn's disease (DUET). https://clinicaltrials.gov/study/NCT04655807.
Panaccione 2015 {published data only}
    1. Panaccione R, Sandborn W, Gordon G, Lee SD, Safdi A, Sedghi S, et al. Briakinumab (anti-interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology 2010;105:S457-8.
    1. Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, et al. Briakinumab for the treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases 2015;21(6):1329-40. - PMC - PubMed
Sands 2009 {published data only}
    1. Sands BE, Jacobson EW, Sylwestrowicz T, Younes Z, Dryden G, Fedorak R, et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflammatory Bowel Diseases 2010;16(7):1209-18. [DOI: 10.1002/ibd.21159] - DOI - PubMed
Ten Bokkel Huinink 2021 {published data only}
    1. Ten Bokkel Huinink S, Biemans V, Duijvestein M, Pierik M, Hoentjen F, West RL, et al. Re-induction with intravenous ustekinumab after secondary loss of response is a valid optimization strategy in Crohn’s disease. European Journal of Gastroenterology & Hepatology 2021;33(1S):e783-88. [DOI: 10.1097/MEG.0000000000002256] - DOI - PubMed

References to studies awaiting assessment

Ihara 2017 {published data only}UMIN000028139
    1. Ihara Y, Kitazono T. Therapeutic reactivity of ustekinumab in moderate to severe active stage Crohn's disease. https://www.rctportal.niph.go.jp/en 2017.

References to ongoing studies

BUUST 2020 {unpublished data only}021200013
    1. Rintaro M. A comparison between combination therapy of ustekinumab boosted by budesonide and monotherapy of ustekinumab for Crohn's disease. (BUUST). https://jrct.niph.go.jp/en-top 2020.
NCT04496063 {unpublished data only}
    1. NCT04496063. Ustekinumab in fistulising perianal Crohn's disease (USTAP). https://clinicaltrials.gov/study/NCT04496063.
NCT04524611 {unpublished data only}
    1. NCT04524611. Study comparing intravenous (IV)/subcutaneous (SC) risankizumab to IV/SC ustekinumab to assess change in Crohn's disease activity index (CDAI) in adult participants with moderate to severe Crohn's disease (CD) (SEQUENCE). https://clinicaltrials.gov/study/NCT04524611.
NCT04629196 {unpublished data only}
    1. NCT04629196. Induction optimization with Stelara for Crohn's disease. https://clinicaltrials.gov/study/NCT04629196.
NCT05928039 {unpublished data only}
    1. NCT05928039. PATHFINDER: Evaluating the optimal first-line treatment strategy for moderate-to-severely active ileal-dominant Crohn's disease. https://clinicaltrials.gov/study/NCT05928039.

Additional references

Ashraf 2023
    1. Ashraf H, Bodapati A, Hanif A, Okafor DK, Katyal G, Kaur G, et al. Safety and efficacy of biologic therapies (ustekinumab and vedolizumab) in the treatment of inflammatory bowel disease (IBD): A systematic review. Cureus 2023;15(11):e48338. [DOI: 10.7759/cureus.48338] - DOI - PMC - PubMed
Avedillo‐Salas 2023
    1. Avedillo-Salas A, Corral-Cativiela S, Fanlo-Villacampa A, Vicente-Romero J. The efficacy and safety of biologic drugs in the treatment of moderate-severe Crohn's disease: A systematic review. Pharmaceuticals (Basel, Switzerland) 2023;16(11):1-26. [DOI: 10.3390/ph16111581] - DOI - PMC - PubMed
Barberio 2023
    1. Barberio B, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: Systematic review and network meta-analysis. Gut 2023;72(2):264-74. [DOI: 10.1136/gutjnl-2022-328052] - DOI - PubMed
Colombel 2007
    1. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132(1):52-65. - PubMed
Covidence [Computer program]
    1. Covidence. Version accessed 22 August 2022. Melbourne, Australia: Veritas Health Innovation, 2022. Available at https://www.covidence.org.
EMA 2011
    1. European Medicines Agency. Ozespa: Withdrawal of the marketing authorisation application. https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/ozespa.
EMA 2016
    1. European Medicines Agency. Stelara. https://www.ema.europa.eu/en/medicines/human/EPAR/stelara.
EMA 2022
    1. European Medicines Agency. Skyrizi. https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi.
Fang 2023
    1. Fang S, Zhang S, Zhang C, Wang L. Effectiveness and safety of ustekinumab for pediatric inflammatory bowel disease: A systematic review. Pediatric Drugs 2023;25(5):499-513. [DOI: 10.1007/s40272-023-00586-7] - DOI - PubMed
FDA 2016
    1. Food and Drug Administration. Stelara. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761044Orig1s000T....
Feuerstein 2021
    1. Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology 2021;160(7):2496-508. [DOI: 10.1053/j.gastro.2021.04.022] - DOI - PMC - PubMed
Fine 2019
    1. Fine S, Papamichael K, Cheifetz AS. Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterology & Hepatology 2019;15(12):656-65. - PMC - PubMed
Ghosh 2024
    1. Ghosh S, Feagan BG, Ott E, Gasink C, Godwin B, Marano C, et al. Safety of ustekinumab in inflammatory bowel disease: Pooled safety analysis through 5 years in Crohn's disease and 4 years in ulcerative colitis. Journal of Crohn's & Colitis 2024;18(7):1091–1101. [DOI: 10.1093/ecco-jcc/jjae013] - DOI - PMC - PubMed
Gottlieb 2009
    1. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373(9664):633-40. - PubMed
Guyatt 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.) 2008;336(7650):924-6. - PMC - PubMed
Hanauer 2002
    1. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-9. - PubMed
Hanauer 2006
    1. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130(2):323-33. - PubMed
Higgins 2011
    1. Higgins JP, Deeks JJ, Altman DG, editor(s). Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
Kotze 2018
    1. Kotze PG, Ma C, Almutairdi A, Panaccione R. Clinical utility of ustekinumab in Crohn's disease. Journal of Inflammation Research 2018;11:35-47. [DOI: 10.2147/JIR.S157358] - DOI - PMC - PubMed
Lichtenstein 2018
    1. Lichtenstein GR, Loftus EV, Isaacs KL, Reguiero MD, Gerson LB, Sands BE. ACG clinical guideline: Management of Crohn's disease in adults. American Journal of Gastroenterology 2018;113(4):481-517. [DOI: 10.1038/ajg.2018.27] - DOI - PubMed
MECIR 2023
    1. Higgins JPT, Lasserson T, Thomas J, Flemyng E, Churchill R. Standards for the conduct of new Cochrane Intervention Reviews. Methodological Expectations of Cochrane Intervention Reviews. Cochrane: London, August 2023.
Meserve 2022
    1. Meserve J, Ma C, Dulai PS, Jairath V, Singh S. Effectiveness of reinduction and/or dose escalation of ustekinumab in Crohn's disease: A systematic review and meta-analysis. Clinical Gastroenterology and Hepatology 2022;20(12):2728-40. [DOI: 10.1016/j.cgh.2021.10.002] - DOI - PMC - PubMed
Ng 2017
    1. Ng SC, Shi HY, Underwood FE, Tang W, Benchimol EI, Panaccione R, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390(10114):2769-78. [DOI: 10.1016/s0140-6736(17)32448-0] - DOI - PubMed
Oren 1997
    1. Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology 1997;92(12):2203-9. - PubMed
Papp 2008
    1. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371(9625):1675-84. [PMID: ] - PubMed
Present 1980
    1. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. New England Journal of Medicine 1980;302(18):981-7. [DOI: 10.1056/NEJM198005013021801] - DOI - PubMed
Reich 2011
    1. Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. New England Journal of Medicine 2011;365(17):1586-96. - PubMed
RevMan 2024 [Computer program]
    1. Review Manager (RevMan). Version 7.12.0. The Cochrane Collaboration, 2024. Available at https://revman.cochrane.org.
Rhodes 1971
    1. Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;298(7737):1273-6. [DOI: 10.1016/S0140-6736(71)90598-8] - DOI - PubMed
Roda 2020
    1. Roda G, Ng SC, Kotze PG, Argollo M, Panaccione R, Spinelli A, et al. Crohn's disease. Nature Reviews Disease Primers 2020;6(1):1-19. [DOI: 10.1038/s41572-020-0156-2] - DOI - PubMed
Rutgeerts 1994
    1. Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn's disease. New England Journal of Medicine 1994;331(13):842-5. - PubMed
Sandborn 2007
    1. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine 2007;357(3):228-38. [DOI: 10.1056/NEJMoa067594] - DOI - PubMed
Sands 2004
    1. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine 2004;350(9):876-85. [DOI: 10.1056/NEJMoa030815] - DOI - PubMed
Schreiber 2007
    1. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. New England Journal of Medicine 2007;357(3):239-50. [DOI: 10.1056/NEJMoa062897] - DOI - PubMed
Schünemann 2011
    1. Schunemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
Shiga 2022
    1. Shiga H, Tarasawa K, Moroi R, Makuuchi M, Takahashi T, Shimoyama Y, et al. Long-term effectiveness of ustekinumab comparable to antitumor necrosis factor agents in patients with Crohn's disease. Journal of Gastroenterology and Hepatology 2022;37(11):2105-12. [DOI: 10.1111/jgh.15992] - DOI - PMC - PubMed
Singh 2021
    1. Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Lancet Gastroenterology & Hepatology 2021;6(12):1002-14. [DOI: 10.1016/S2468-1253(21)00312-5] - DOI - PMC - PubMed
Solitano 2023
    1. Solitano V, Facciorusso A, Jess T, Ma C, Hassan C, Repici A, et al. Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: A systematic review and meta-analysis. Clinical Gastroenterology and Hepatology 2023;21(4):907-21.e2. [DOI: 10.1016/j.cgh.2022.07.032] - DOI - PubMed
Sterne 2019
    1. Sterne JA, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:I4898. - PubMed
Summers 1979
    1. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77(4 Part 2):847-69. - PubMed
Torres 2017
    1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet 2017;389(10080):1741-55. [DOI: 10.1016/S0140-6736(16)31711-1] - DOI - PubMed
Torres 2020
    1. Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn's disease: Medical treatment. Journal of Crohn's & Colitis 2020;14(1):4-22. [DOI: 10.1093/ecco-jcc/jjz180] - DOI - PubMed
Turner 2021
    1. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021;160(5):1570-83. [DOI: 10.1053/j.gastro.2020.12.031] - DOI - PubMed
Uhlig 2018
    1. Uhlig HH, Powrie F. Translating immunology into therapeutic concepts for inflammatory bowel disease. Annual Review of Immunology 2018;36:755-81. [DOI: 10.1146/annurev-immunol-042617-053055] - DOI - PubMed
Van Andel 2020
    1. Van Andel EM, Koopmann BD, Crouwel F, Noomen CG, De Boer NK, Van Asseldonk DP, et al. Systematic review of development and content validity of patient-reported outcome measures in inflammatory bowel disease: Do we measure what we measure? Journal of Crohn's & Colitis 2020;14(9):1299-315. [DOI: 10.1093/ecco-jcc/jjaa057] - DOI - PMC - PubMed
Vuyyuru 2023
    1. Vuyyuru SK, Solitano V, Hogan M, MacDonald JK, Zayadi A, Parker CE, et al. Efficacy and safety of IL-12/23 and IL-23 inhibitors for Crohn's disease: Systematic review and meta-analysis. Digestive Diseases and Sciences 2023;68(9):3702-13. [DOI: 10.1007/s10620-023-08014-z] - DOI - PMC - PubMed
Vuyyuru 2024
    1. Vuyyuru SK, Nguyen TM, Murad MH, Narula N, Bessissow T, Zou G, et al. Comparative efficacy of advanced therapies for achieving endoscopic outcomes in Crohn's disease: A systematic review and network meta-analysis. Clinical Gastroenterology and Hepatology 2024;22(6):1190-99.e15. [DOI: 10.1016/j.cgh.2023.12.023] - DOI - PubMed

References to other published versions of this review

Khanna 2015
    1. Khanna R, Preiss JC, MacDonald JK, Timmer A. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2015, Issue 5. Art. No: CD007572. [DOI: 10.1002/14651858.CD007572.pub2] - DOI - PubMed
MacDonald 2016
    1. MacDonald JK, Nguyen TM, Khanna R, Timmer A. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No: CD007572. [DOI: 10.1002/14651858.CD007572.pub3] - DOI - PMC - PubMed

MeSH terms

Associated data

LinkOut - more resources